Dynavax Technologies (DVAX) -33% premarket after the FDA rejects its hepatitis B vaccine...
Monday, February 25, 8:10 AM ETDynavax Technologies (DVAX) -33% premarket after the FDA rejects its hepatitis B vaccine Heplisav, citing the need for additional safety data in healthy adults. DVAX says it's confident it can meet the request for more information, but it may also fast-track a refiling by first seeking approval for sick patients.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles